SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FMC Corporation to Issue Quarterly Dividend of $0.08 (NYSE:FMC)

FMC Corporation (NYSE:FMC) announced a quarterly dividend on Friday, December 12th. Stockholders of record on Wednesday, December 31st will be paid a dividend of 0.08 per share by the basic materials...

FMC Corporation (NYSE:FMC) Receives Consensus Rating of "Hold" from Analysts

Shares of FMC Corporation (NYSE:FMC - Get Free Report) have been assigned an average rating of "Hold" from the sixteen research firms that are covering the firm, MarketBeat reports. Three investment...

FMC Corporation announces date for fourth quarter 2025 earnings release and webcast conference call

FMC Corporation announces date for fourth quarter 2025 earnings release and webcast conference call FMC Corporation announces date for fourth quarter 2025 earnings release and webcast conference call...

FMC (NYSE:FMC) Trading Up 5.4% - Time to Buy?

FMC (NYSE:FMC) Trading 5.4% Higher - Time to Buy...

If You Had Invested $3,000 in FMC Stock 1 Year Ago, Here's How Much You Would Have Today

Key PointsFMC's stock has badly underperformed the S&P 500...

FMC Corporation Declares Quarterly Dividend

FMC Corporation Declares Quarterly Dividend FMC Corporation Declares Quarterly Dividend PR Newswire PHILADELPHIA, Dec. 12, 2025 PHILADELPHIA, Dec. 12, 2025 /PRNewswire/ -- FMC Corporation (NYSE: FMC...

<ul class="summary-bullets"><li>The insecticide and herbicide maker projected 2025 revenue of $3.92 billion to $4.02 billion in October, down from its previous forecast of $4.08 billion to $4.28 billion.</li><li>The research firm stated that FMC faces a "tough" near-to-medium-term outlook, with management citing only limited growth potential over the next three years, the analyst noted.</li><li>FMC previously warned that it would continue to grapple with tepid prices amid a high influx of generic products.</li></ul>FMC stock slipped over 1% in premarket trading on Tuesday, after Barclays turned less optimistic about the company’s near-term results.As per TheFly, Barclays analyst Benjamin Theurer downgraded FMC to ‘Underweight’ from ‘Equal Weight’ and lowered the price target to $13 from $16. The new price target was marginally below FMC stock’s Monday closing price of $13.10. FMC stock has fallen by over 73% this year.<h2 class="st-heading-2">What Did The Analyst Say?</h2>The Barclays analyst expects the agriculture markets to see mixed results in 2026. The research firm stated that FMC faces a "tough" near-to-medium-term outlook, with management citing only limited growth potential over the next three years.The insecticide and herbicide maker projected 2025 revenue of $3.92 billion to $4.02 billion in October, down from its previous forecast of $4.08 billion to $4.28 billion. FMC also cut its earnings-per-share estimates to $2.92 to $3.14, down from $3.26 to $3.70 earlier.FMC stated pricing is expected to have a mid-to-high single-digit percentage-point impact on its full-year earnings, as it continues to grapple with a high influx of generic products, which are hampering sales of the company’s proprietary products. Its Latin American sales fell 8% year over year in the third quarter.The company added that low customer liquidity caused credit constraints in Brazil and Argentina, further inhibiting growth. Prices of key crops such as soybeans and corn have remained under pressure for much of the year, prompting farmers to cut spending on insecticides and fungicides.<h2 class="st-heading-2">Debt Relief</h2>On Monday, FMC amended its credit agreement to ease financial covenants and extend its covenant relief period to 2028. The amendment also limits subsidiary indebtedness to a maximum aggregate outstanding principal amount of $350 million, subject to certain exceptions. It limits increases to the company’s regular quarterly dividend above $0.08 per share.<h2 class="st-heading-2">What Are Stocktwits Users Thinking?</h2>Retail sentiment on Stocktwits about <a href="https://stocktwits.com/symbol/FMC">FMC</a> was in ‘neutral’ territory at the time of writing, compared to ‘bearish’ a day earlier.<figure class="image"><img style="aspect-ratio:718/89;" src="https://news.stocktwits-cdn.com/FMC_Dec_9_JPG_f7e1cf1f20.webp" alt="FMC’s Sentiment Meter and Message Volume as of 08:17 a.m. ET on Dec. 9, 2025 | Source: Stocktwits" width="718" height="89"><figcaption>FMC’s Sentiment Meter and Message Volume as of 08:17 a.m. ET on Dec. 9, 2025 | Source: Stocktwits</figcaption></figure>One user on Stocktwits said he expects the share price to cross $50 by 2028 as new products get introduced, after the banks gave the company more time to recover.<a href="https://stocktwits.com/ssdsddssd2/message/638580327">https://stocktwits.com/ssdsddssd2/message/638580327</a>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cemtrex-stock-in-spotlight-after-a-year-of-turbulence/cLIruf8REZB">Cemtrex Stock In Spotlight After A Year Of Turbulence — A Look At Some Of The Strategic Moves This Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FMC Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pesticide Maker's Stock Has Slid Over 73% In 2025 — Barclays Sees Further Pain

Barclays analyst Benjamin Theurer downgraded FMC to ‘Underweight’ from ‘Equal Weight’ and lowered the price target to $13 from $16.

Equity

ADM (ADM) Up 6.2% Since Last Earnings Report: Can It Continue?

ADM (ADM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street's Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend Yields

FMC Corporation (NYSE:FMC) Receives Consensus Recommendation of "Hold" from Analysts

Shares of FMC Corporation (NYSE:FMC - Get Free Report) have been given a consensus rating of "Hold" by the sixteen analysts that are presently covering the company, MarketBeat reports. Two investment...

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC
FMC Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FMC News

FMCFMC Corp.